|
|
|
|
| LEADER |
03005 am a22004213u 4500 |
| 001 |
113321 |
| 042 |
|
|
|a dc
|
| 100 |
1 |
0 |
|a Schneider, Martin W
|e author
|
| 100 |
1 |
0 |
|a Institute for Medical Engineering and Science
|e contributor
|
| 100 |
1 |
0 |
|a Massachusetts Institute of Technology. Department of Biological Engineering
|e contributor
|
| 100 |
1 |
0 |
|a Massachusetts Institute of Technology. Department of Biology
|e contributor
|
| 100 |
1 |
0 |
|a Massachusetts Institute of Technology. Department of Brain and Cognitive Sciences
|e contributor
|
| 100 |
1 |
0 |
|a McGovern Institute for Brain Research at MIT
|e contributor
|
| 100 |
1 |
0 |
|a Gao, Linyi
|e contributor
|
| 100 |
1 |
0 |
|a Cox, David Benjamin Turitz
|e contributor
|
| 100 |
1 |
0 |
|a Yan, Winston Xia
|e contributor
|
| 100 |
1 |
0 |
|a Manteiga, John Colonnese
|e contributor
|
| 100 |
1 |
0 |
|a Zhang, Feng
|e contributor
|
| 700 |
1 |
0 |
|a Yamano, Takashi
|e author
|
| 700 |
1 |
0 |
|a Nishimasu, Hiroshi
|e author
|
| 700 |
1 |
0 |
|a Nureki, Osamu
|e author
|
| 700 |
1 |
0 |
|a Crosetto, Nicola
|e author
|
| 700 |
1 |
0 |
|a Gao, Linyi
|e author
|
| 700 |
1 |
0 |
|a Cox, David Benjamin Turitz
|e author
|
| 700 |
1 |
0 |
|a Yan, Winston Xia
|e author
|
| 700 |
1 |
0 |
|a Manteiga, John Colonnese
|e author
|
| 700 |
1 |
0 |
|a Zhang, Feng
|e author
|
| 245 |
0 |
0 |
|a Engineered Cpf1 variants with altered PAM specificities
|
| 260 |
|
|
|b Nature Publishing Group,
|c 2018-01-29T16:03:54Z.
|
| 856 |
|
|
|z Get fulltext
|u http://hdl.handle.net/1721.1/113321
|
| 520 |
|
|
|a The RNA-guided endonuclease Cpf1 is a promising tool for genome editing in eukaryotic cells. However, the utility of the commonly used Acidaminococcus sp. BV3L6 Cpf1 (AsCpf1) and Lachnospiraceae bacterium ND2006 Cpf1 (LbCpf1) is limited by their requirement of a TTTV protospacer adjacent motif (PAM) in the DNA substrate. To address this limitation, we performed a structure-guided mutagenesis screen to increase the targeting range of Cpf1. We engineered two AsCpf1 variants carrying the mutations S542R/K607R and S542R/K548V/N552R, which recognize TYCV and TATV PAMs, respectively, with enhanced activities in vitro and in human cells. Genome-wide assessment of off-target activity using BLISS indicated that these variants retain high DNA-targeting specificity, which we further improved by introducing an additional non-PAM-interacting mutation. Introducing the identified PAM-interacting mutations at their corresponding positions in LbCpf1 similarly altered its PAM specificity. Together, these variants increase the targeting range of Cpf1 by approximately threefold in human coding sequences to one cleavage site per ~11 bp.
|
| 520 |
|
|
|a National Institute of General Medical Sciences (U.S.) (Grant T32GM007753)
|
| 520 |
|
|
|a National Institute of General Medical Sciences (U.S.) (Grant T32GM007753)
|
| 520 |
|
|
|a National Institutes of Health (U.S.) (Grant 2T32GM7287-41)
|
| 520 |
|
|
|a National Institute of Mental Health (U.S.) (Grant 5DP1-MH100706)
|
| 520 |
|
|
|a National Institute of Mental Health (U.S.) (Grant 1R01-MH110049)
|
| 655 |
7 |
|
|a Article
|
| 773 |
|
|
|t Nature Biotechnology
|
